Evidence map›Paper›PMID 41315466›Full record

ArticleScientific reports2025

Classifying the tumor immune microenvironment in cervical cancer based on nuclear cytoplasmic consistent genes.

Jiawei Wang, Anji Chen, Qiuling Chen, Haoting Niu, Ying Mao, Xiang Hu, Shuanglin Xiang, Jun He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiawei Wang *Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Hunan Normal University Affiliated Changsha Hospital for Maternal and Child Health Care, Changsha, China.
Anji Chen *Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Hunan Normal University Affiliated Changsha Hospital for Maternal and Child Health Care, Changsha, China.
Qiuling Chen *Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Hunan Normal University Affiliated Changsha Hospital for Maternal and Child Health Care, Changsha, China.
Haoting Niu *State Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, Changsha, China.
Ying MaoState Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, Changsha, China.
Xiang HuState Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, Changsha, China. huxiang@hunnu.edu.cn.
Shuanglin XiangEngineering Research Center for Antibodies From Experimental Animals of Hunan Province, College of Life Sciences, Hunan Normal University, Changsha, China. xshlin@hunnu.edu.cn.
Jun HeHunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Hunan Normal University Affiliated Changsha Hospital for Maternal and Child Health Care, Changsha, China. hejun280@hunnu.edu.cn.

Funding

Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control HPKL2023005Innovation and entrepreneurship fund for college students of Hunan Normal University 2023275Key Research and Development Program of Hunan Province 2024DK2002
6 · The paper itself

Abstract

Treatment options for advanced or recurrent cervical cancer (CC) remain limited, highlighting the urgent need for effective molecular biomarkers and therapeutic strategies. This study investigates nuclear-cytoplasmic consistent genes (NCCGs) in CC and other epithelial-derived malignancies, exploring their potential in molecular subtyping, prognosis evaluation, and therapeutic response prediction. NCCGs were identified using single-cell sequencing and single-nucleus RNA sequencing data. Through Cox regression and single-sample gene set enrichment analysis, TCGA-CESC cohort were stratified into high-risk (HRG) and low-risk (LRG) groups. Pan-cancer analysis of 14 TCGA epithelial-derived malignancies, including BLCA and BRCA, validated the classification capability and prognostic relevance of NCCGs. Clinical utility in predicting chemotherapy and immunotherapy responses was assessed using GSE168009 and IMvigor210CoreBiologies cohorts. NCCGs effectively stratified CC cohort into HRG and LRG. LRG demonstrated significantly better survival (HR = 3.24, 95% CI 1.57-6.7) and higher immune scores, including elevated CD8

Indexed as

Cell NucleusCytoplasmTumor MicroenvironmentUterine Cervical NeoplasmsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansPrognosisSingle-Cell AnalysisBiomarkers, TumorCervical cancerNuclear-cytoplasmic consistent genesPrognostic biomarkers and risk stratificationSingle-cell and single-nucleus RNA sequencingTumor microenvironment

Identifiers

PMID41315466
PMCPMC12663427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.